Insulin sensitizers and heart failure: An engine flooded with fuel

Current Hypertension Reports

Volumn 12, Issue 6, 2010, Pages 399-401

  Khalaf, Khaled I ^a   Taegtmeyer, Heinrich ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN SENSITIZING AGENT; PIOGLITAZONE; ROSIGLITAZONE;

ACUTE HEART INFARCTION; AGED; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG FATALITY; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; NOTE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; STROKE;

EID: 78649908200     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-010-0158-7     Document Type: Note

References (14)

1. Medical Officer's Review of New Drug Application 21-071-Rosiglitazone (AVANDIA). Center for Drug Evaluation and Research, US Food and Drug Administration, 1999. http://www.accessdata.fda.gov/drugsatfda-docs/nda/99/ 21071-Avandia-medr.pdf. Accessed September 17, 2010.
2. SE Nissen K Wolski 2007 Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457 2471 1:CAS:528:DC%2BD2sXms1SisrY%3D 10.1056/NEJMoa072761 17517853
3. US Food and Drug Administration: Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemiology. Joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Briefing Document 30 July 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder. pdf. Accessed September 17, 2010.
4. PD Home SJ Pocock H Beck-Nielsen, et al. 2009 Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2125 2135 1:CAS:528:DC%2BD1MXnsFSis78%3D 10.1016/S0140-6736(09)60953-3 19501900
5. SE Nissen 2010 The rise and fall of rosiglitazone Eur Heart J 31 773 776 1:CAS:528:DC%2BC3cXkt1Kktbk%3D 10.1093/eurheartj/ehq016 20154334
6. Nissen SE, Wolski K: Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010 June 28 (Epub ahead of print).
7. A Benbow M Stewart G Yeoman 2001 Thiazolidinediones for type 2 diabetes. All glitazones may exacerbate heart failure BMJ 322 236 1:STN:280: DC%2BD3M7kt1Sitg%3D%3D 10.1136/bmj.322.7280.236 11159623
8. AM Lincoff K Wolski SJ Nicholls, et al. 2007 Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials JAMA 298 1180 1188 1:CAS:528:DC%2BD2sXhtVGmtL3J 10.1001/jama.298.10.1180 17848652 (Pubitemid 47403104)
9. D Aguilar B Bozkurt K Ramasubbu, et al. 2009 Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes J Am Coll Cardiol 54 422 428 1:CAS:528:DC%2BD1MXhtVOmsbrK 10.1016/j.jacc.2009.04.049 19628117
10. HC Gerstein ME Miller RP Byington, et al. 2008 Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545 2559 1:CAS:528:DC%2BD1cXnt1Wjs7s%3D 10.1056/NEJMoa0802743 18539917 (Pubitemid 351831356)
11. K Kalantar-Zadeh G Block T Horwich, et al. 2004 Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure J Am Coll Cardiol 43 1439 1444 10.1016/j.jacc.2003.11.039 15093881 (Pubitemid 38496352)
12. D Jagasia JM Whiting J Concato, et al. 2001 Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease Circulation 103 1734 1739 1:CAS:528:DC%2BD3MXjsFGntro%3D 11282903
13. CM Kolka LN Harrison M Lottati, et al. 2010 Diet-induced obesity prevents interstitial dispersion of insulin in skeletal muscle Diabetes 59 619 626 1:CAS:528:DC%2BC3cXjslegtb4%3D 10.2337/db09-0839 19959760
14. H Taegtmeyer R Hems HA Krebs 1980 Utilization of energy-providing substrates in the isolated working rat heart Biochem J 186 701 711 1:CAS:528:DyaL3cXkt1ehurw%3D 6994712